DNA Editing by APOBECs: A Genomic Preserver and Transformer

Trends in Genetics

Volumn 32, Issue 1, 2016, Pages 16-28

  Knisbacher, Binyamin A ^a   Gerber, Doron ^a   Levanon, Erez Y ^a  

^a BAR ILAN UNIVERSITY   (Israel)

Author keywords

AID; APOBEC; C to U editing; DNA editing; Genome evolution; Retrotransposons

Indexed keywords

ACTIVATION INDUCED CYTIDINE DEAMINASE; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 1; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 2; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 4; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 5; DEOXYCYTIDINE; DEOXYURIDINE; DNA; GENOMIC DNA; UNCLASSIFIED DRUG; APOBEC3 PROTEIN, HUMAN; APOBEC4 PROTEIN, HUMAN; APOLIPOPROTEIN B MRNA EDITING ENZYME CATALYTIC POLYPEPTIDE LIKE; CYTIDINE DEAMINASE; CYTOSINE DEAMINASE; RETROPOSON;

ADAPTIVE IMMUNITY; ANTIBODY SPECIFICITY; DEAMINATION; DEMETHYLATION; DNA EDITING; ENZYME ACTIVITY; EPIGENETICS; GENE CONTROL; GENE CONVERSION; GENE EXPRESSION REGULATION; GENOMIC INSTABILITY; GENOMICS; HUMAN; INNATE IMMUNITY; NONHUMAN; NUCLEIC ACID STRUCTURE, METABOLISM AND FUNCTION; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; RETROPOSON; REVIEW; RNA EDITING; SOMATIC HYPERMUTATION; ANIMAL; GENETIC EPIGENESIS; GENETICS; GENOME; IMMUNOLOGY; METABOLISM; MOLECULAR EVOLUTION;

ANIMALS; APOBEC DEAMINASES; CYTIDINE DEAMINASE; CYTOSINE DEAMINASE; DNA; EPIGENESIS, GENETIC; EVOLUTION, MOLECULAR; GENOME; HUMANS; IMMUNITY, INNATE; RETROELEMENTS;

EID: 84951569633     PISSN: 01689525     EISSN: 13624555     Source Type: Journal    
DOI: 10.1016/j.tig.2015.10.005     Document Type: Review

References (144)

1. Koito A., Ikeda T. Apolipoprotein B mRNA-editing, catalytic polypeptide cytidine deaminases and retroviral restriction. Wiley Interdiscip. Rev. RNA 2012, 3:529-541.
2. Arias J.F., et al. Retroelements versus APOBEC3 family members: no great escape from the magnificent seven. Front. Microbiol. 2012, 3:275.
3. Moris A., et al. AID and APOBECs span the gap between innate and adaptive immunity. Front. Microbiol. 2014, 5:534.
4. Harris R.S., Dudley J.P. APOBECs and virus restriction. Virology 2015, 479:131-145.
5. Roberts S.A., Gordenin D.A. Hypermutation in human cancer genomes: footprints and mechanisms. Nat. Rev. Cancer 2014, 14:786-800.
6. Henderson S., Fenton T. APOBEC3 genes: retroviral restriction factors to cancer drivers. Trends Mol. Med. 2015, 21:274-284.
7. Swanton C., et al. APOBEC enzymes: mutagenic fuel for cancer evolution and heterogeneity. Cancer Discov. 2015, 5:704-712.
8. Rebhandl S., et al. AID/APOBEC deaminases and cancer. Oncoscience 2015, 2:320-333.
9. Bhutani N., et al. DNA demethylation dynamics. Cell 2011, 146:866-872.
10. Franchini D-M., et al. 5-Methylcytosine DNA demethylation: more than losing a methyl group. Annu. Rev. Genet. 2012, 46:419-441.
11. Ramiro A.R., Barreto V.M. Activation-induced cytidine deaminase and active cytidine demethylation. Trends Biochem. Sci. 2015, 40:172-181.
12. Knisbacher B.A., Levanon E.Y. DNA and RNA editing of retrotransposons accelerate mammalian genome evolution. Ann. N. Y. Acad. Sci. 2015, 1341:115-125.
13. Conticello S.G. The AID/APOBEC family of nucleic acid mutators. Genome Biol. 2008, 9:229.
14. Severi F., et al. Analysis of reptilian APOBEC1 suggests that RNA editing may not be its ancestral function. Mol. Biol. Evol. 2011, 28:1125-1129.
15. Refsland E.W., Harris R.S. The APOBEC3 family of retroelement restriction factors. Curr. Top. Microbiol. Immunol. 2013, 371:1-27.
16. Muramatsu M., et al. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 2000, 102:553-563.
17. Hwang J.K., et al. Related mechanisms of antibody somatic hypermutation and class switch recombination. Microbiol. Spectr. 2015, 3. MDNA3-0037-2014.
18. Chen Z., Wang J.H. Generation and repair of AID-initiated DNA lesions in B lymphocytes. Front. Med. 2014, 8:201-216.
19. Péron S., et al. AID-driven deletion causes immunoglobulin heavy chain locus suicide recombination in B cells. Science 2012, 336:931-934.
20. Morgan H.D., et al. Activation-induced cytidine deaminase deaminates 5-methylcytosine in DNA and is expressed in pluripotent tissues: implications for epigenetic reprogramming. J. Biol. Chem. 2004, 279:52353-52360.
21. MacDuff D.a., et al. AID can restrict L1 retrotransposition suggesting a dual role in innate and adaptive immunity. Nucleic Acids Res. 2009, 37:1854-1867.
22. Popp C., et al. Genome-wide erasure of DNA methylation in mouse primordial germ cells is affected by AID deficiency. Nature 2010, 463:1101-1105.
23. Liu M., et al. Two levels of protection for the B cell genome during somatic hypermutation. Nature 2008, 451:841-845.
24. Robbiani D.F., et al. AID is required for the chromosomal breaks in c-myc that lead to c-myc/IgH translocations. Cell 2008, 135:1028-1038.
25. Hasham M.G., et al. Widespread genomic breaks generated by activation-induced cytidine deaminase are prevented by homologous recombination. Nat. Immunol. 2010, 11:820-826.
26. Chiarle R., et al. Genome-wide translocation sequencing reveals mechanisms of chromosome breaks and rearrangements in B cells. Cell 2011, 147:107-119.
27. Klein I.A., et al. Translocation-capture sequencing reveals the extent and nature of chromosomal rearrangements in B lymphocytes. Cell 2011, 147:95-106.
28. Yamane A., et al. Deep-sequencing identification of the genomic targets of the cytidine deaminase AID and its cofactor RPA in B lymphocytes. Nat. Immunol. 2011, 12:62-69.
29. Kato L., et al. Nonimmunoglobulin target loci of activation-induced cytidine deaminase (AID) share unique features with immunoglobulin genes. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:2479-2484.
30. Buerstedde J-M., et al. Induction of homologous recombination between sequence repeats by the activation induced cytidine deaminase (AID) protein. Elife 2014, 3:e03110.
31. Liang G., et al. RNA editing of hepatitis B virus transcripts by activation-induced cytidine deaminase. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:2246-2251.
32. Pasqualucci L., et al. AID is required for germinal center-derived lymphomagenesis. Nat. Genet. 2008, 40:108-112.
33. Daniels T.F., et al. Lipoproteins, cholesterol homeostasis and cardiac health. Int. J. Biol. Sci. 2009, 5:474-488.
34. Rosenberg B.R., et al. Transcriptome-wide sequencing reveals numerous APOBEC1 mRNA-editing targets in transcript 3' UTRs. Nat. Struct. Mol. Biol. 2011, 18:230-236.
35. Blanc V., et al. Genome-wide identification and functional analysis of Apobec-1-mediated C-to-U RNA editing in mouse small intestine and liver. Genome Biol. 2014, 15:R79.
36. Mehta A., et al. Molecular cloning of apobec-1 complementation factor, a novel RNA-binding protein involved in the editing of apolipoprotein B mRNA. Mol. Cell. Biol. 2000, 20:1846-1854.
37. Fossat N., et al. C to U RNA editing mediated by APOBEC1 requires RNA-binding protein RBM47. EMBO Rep. 2014, 15:903-910.
38. Anant S., Davidson N.O. An AU-rich sequence element (UUUN[A/U]U) downstream of the edited C in apolipoprotein B mRNA is a high-affinity binding site for Apobec-1: binding of Apobec-1 to this motif in the 3' untranslated region of c-myc increases mRNA stability. Mol. Cell. Biol. 2000, 20:1982-1992.
39. Shimizu Y., et al. The RNA-editing enzyme APOBEC1 requires heterogeneous nuclear ribonucleoprotein Q isoform 6 for efficient interaction with interleukin-8 mRNA. J. Biol. Chem. 2014, 289:26226-26238.
40. Harris R.S., et al. RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators. Mol. Cell 2002, 10:1247-1253.
41. Ikeda T., et al. Intrinsic restriction activity by apolipoprotein B mRNA editing enzyme APOBEC1 against the mobility of autonomous retrotransposons. Nucleic Acids Res. 2011, 39:5538-5554.
42. Liao W., et al. APOBEC-2, a cardiac- and skeletal muscle-specific member of the cytidine deaminase supergene family. Biochem. Biophys. Res. Commun. 1999, 260:398-404.
43. Anant S., et al. ARCD-1, an apobec-1-related cytidine deaminase, exerts a dominant negative effect on C to U RNA editing. Am. J. Physiol. Cell Physiol. 2001, 281:C1904-C1916.
44. Li J., et al. APOBEC2 mRNA and protein is predominantly expressed in skeletal and cardiac muscles of chickens. Gene 2014, 539:263-269.
45. Mikl M.C., et al. Mice deficient in APOBEC2 and APOBEC3. Mol. Cell. Biol. 2005, 25:7270-7277.
46. Sato Y., et al. Deficiency in APOBEC2 leads to a shift in muscle fiber type, diminished body mass, and myopathy. J. Biol. Chem. 2010, 285:7111-7118.
47. Etard C., et al. Lack of Apobec2-related proteins causes a dystrophic muscle phenotype in zebrafish embryos. J. Cell Biol. 2010, 189:527-539.
48. Vonica A., et al. APOBEC2, a selective inhibitor of TGFβ signaling, regulates left-right axis specification during early embryogenesis. Dev. Biol. 2011, 350:13-23.
49. Powell C., et al. Injury-dependent Müller glia and ganglion cell reprogramming during tissue regeneration requires Apobec2a and Apobec2b. J. Neurosci. 2012, 32:1096-1109.
50. Powell C., et al. Zinc-binding domain-dependent, deaminase-independent actions of apolipoprotein B mRNA-editing enzyme, catalytic polypeptide 2 (Apobec2), mediate its effect on zebrafish retina regeneration. J. Biol. Chem. 2014, 289:6007.
51. Rai K., et al. DNA demethylation in zebrafish involves the coupling of a deaminase, a glycosylase, and gadd45. Cell 2008, 135:1201-1212.
52. Shimoda N., et al. No evidence for AID/MBD4-coupled DNA demethylation in zebrafish embryos. PLoS ONE 2014, 9:e114816.
53. Norman J.M., et al. The antiviral factor APOBEC3G enhances the recognition of HIV-infected primary T cells by natural killer cells. Nat. Immunol. 2011, 12:975-983.
54. Casartelli N., et al. The antiviral factor APOBEC3G improves CTL recognition of cultured HIV-infected T cells. J. Exp. Med. 2010, 207:39-49.
55. Beck-Engeser G.B., et al. APOBEC3 enzymes restrict marginal zone B cells. Eur. J. Immunol. 2015, 45:695-704.
56. Sharma S., et al. APOBEC3A cytidine deaminase induces RNA editing in monocytes and macrophages. Nat. Commun. 2015, 6:6881.
57. Suspène R., et al. Somatic hypermutation of human mitochondrial and nuclear DNA by APOBEC3 cytidine deaminases, a pathway for DNA catabolism. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:4858-4863.
58. Stenglein M.D., et al. APOBEC3 proteins mediate the clearance of foreign DNA from human cells. Nat. Struct. Mol. Biol. 2010, 17:222-229.
59. Rogozin I.B., et al. APOBEC4, a new member of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases predicted by computational analysis. Cell Cycle 2005, 4:1281-1285.
60. Lada a.G., et al. Mutator effects and mutation signatures of editing deaminases produced in bacteria and yeast. Biochemistry (Mosc.) 2011, 76:131-146.
61. LaRue R.S., et al. Guidelines for naming nonprimate APOBEC3 genes and proteins. J. Virol. 2009, 83:494-497.
62. Zhang J., Webb D.M. Rapid evolution of primate antiviral enzyme APOBEC3G. Hum. Mol. Genet. 2004, 13:1785-1791.
63. Sawyer S.L., et al. Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G. PLoS Biol. 2004, 2:E275.
64. Jarmuz A., et al. An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 2002, 79:285-296.
65. Sheehy A.M., et al. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002, 418:646-650.
66. Münk C., et al. Functions, structure, and read-through alternative splicing of feline APOBEC3 genes. Genome Biol. 2008, 9:R48.
67. LaRue R.S., et al. The artiodactyl APOBEC3 innate immune repertoire shows evidence for a multi-functional domain organization that existed in the ancestor of placental mammals. BMC Mol. Biol. 2008, 9:104.
68. Münk C., et al. An ancient history of gene duplications, fusions and losses in the evolution of APOBEC3 mutators in mammals. BMC Evol. Biol. 2012, 12:71.
69. Mariani R., et al. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 2003, 114:21-31.
70. Zielonka J., et al. Restriction of equine infectious anemia virus by equine APOBEC3 cytidine deaminases. J. Virol. 2009, 83:7547-7559.
71. Harari A., et al. Polymorphisms and splice variants influence the antiretroviral activity of human APOBEC3H. J. Virol. 2009, 83:295-303.
72. Thielen B.K., et al. Innate immune signaling induces high levels of TC-specific deaminase activity in primary monocyte-derived cells through expression of APOBEC3A isoforms. J. Biol. Chem. 2010, 285:27753-32766.
73. Sheehy A.M., Erthal J. APOBEC3 versus Retroviruses, Immunity versus Invasion: Clash of the Titans. Mol. Biol. Int. 2012, 2012:974924.
74. Vartanian J-P., et al. Evidence for editing of human papillomavirus DNA by APOBEC3 in benign and precancerous lesions. Science 2008, 320:230-233.
75. Narvaiza I., et al. Deaminase-independent inhibition of parvoviruses by the APOBEC3A cytidine deaminase. PLoS Pathog. 2009, 5:e1000439.
76. Peng Z-G., et al. Host apolipoprotein B messenger RNA-editing enzyme catalytic polypeptide-like 3G is an innate defensive factor and drug target against hepatitis C virus. Hepatology 2011, 53:1080-1089.
77. Fehrholz M., et al. The innate antiviral factor APOBEC3G targets replication of measles, mumps and respiratory syncytial viruses. J. Gen. Virol. 2012, 93:565-576.
78. Turelli P., et al. Inhibition of hepatitis B virus replication by APOBEC3G. Science 2004, 303:1829.
79. Bishop K.N., et al. APOBEC-mediated editing of viral RNA. Science 2004, 305:645.
80. Ikeda T., et al. The antiretroviral potency of APOBEC1 deaminase from small animal species. Nucleic Acids Res. 2008, 36:6859-6871.
81. Renard M., et al. APOBEC1 and APOBEC3 cytidine deaminases as restriction factors for hepadnaviral genomes in non-humans in vivo. J. Mol. Biol. 2010, 400:323-334.
82. Gee P., et al. APOBEC1-mediated editing and attenuation of herpes simplex virus 1 DNA indicate that neurons have an antiviral role during herpes simplex encephalitis. J. Virol. 2011, 85:9726-9736.
83. Lindič N., et al. Differential inhibition of LINE1 and LINE2 retrotransposition by vertebrate AID/APOBEC proteins. Retrovirology 2013, 10:156.
84. Barrett B.S., et al. Reassessment of murine APOBEC1 as a retrovirus restriction factor in vivo. Virology 2014, 468-470:601-608.
85. Refsland E.W., et al. Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction. Nucleic Acids Res. 2010, 38:4274-4284.
86. Vieira V.C., Soares M.A. The role of cytidine deaminases on innate immune responses against human viral infections. Biomed. Res. Int. 2013, 2013:683095.
87. Rosser J.M., An W. L1 expression and regulation in humans and rodents. Front. Biosci. 2012, 4:2203-2225.
88. Dewannieux M., Heidmann T. Endogenous retroviruses: acquisition, amplification and taming of genome invaders. Curr. Opin. Virol. 2013, 3:646-656.
89. Cordaux R., Batzer M.A. The impact of retrotransposons on human genome evolution. Nat. Rev. Genet. 2009, 10:691-703.
90. Kinomoto M., et al. All APOBEC3 family proteins differentially inhibit LINE-1 retrotransposition. Nucleic Acids Res. 2007, 35:2955-2964.
91. Koyama T., et al. APOBEC3G oligomerization is associated with the inhibition of both Alu and LINE-1 retrotransposition. PLoS ONE 2013, 8:e84228.
92. Turelli P., et al. The innate antiretroviral factor APOBEC3G does not affect human LINE-1 retrotransposition in a cell culture assay. J. Biol. Chem. 2004, 279:43371-43373.
93. Muckenfuss H., et al. APOBEC3 proteins inhibit human LINE-1 retrotransposition. J. Biol. Chem. 2006, 281:22161-22172.
94. Bogerd H.P., et al. Cellular inhibitors of long interspersed element 1 and Alu retrotransposition. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:8780-8785.
95. Wissing S., et al. Endogenous APOBEC3B restricts LINE-1 retrotransposition in transformed cells and human embryonic stem cells. J. Biol. Chem. 2011, 286:36427-36437.
96. Marchetto M.C.N., et al. Differential L1 regulation in pluripotent stem cells of humans and apes. Nature 2013, 503:525-529.
97. Koito A., Ikeda T. Intrinsic restriction activity by AID/APOBEC family of enzymes against the mobility of retroelements. Mob. Genet. Elements 2011, 1:197-202.
98. Esnault C., et al. APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses. Nature 2005, 433:430-433.
99. Anwar F., et al. Footprint of APOBEC3 on the genome of human retroelements. J. Virol. 2013, 87:8195-8204.
100. Carmi S., et al. Large-scale DNA editing of retrotransposons accelerates mammalian genome evolution. Nat. Commun. 2011, 2:519.
101. Rose P.P., Korber B.T. Detecting hypermutations in viral sequences with an emphasis on G -> A hypermutation. Bioinformatics 2000, 16:400-401.
102. Matsen F.A., et al. A novel Bayesian method for detection of APOBEC3-mediated hypermutation and its application to zoonotic transmission of simian foamy viruses. PLoS Comput. Biol. 2014, 10:e1003493.
103. Chelico L., et al. APOBEC3G DNA deaminase acts processively 3' -> 5' on single-stranded DNA. Nat. Struct. Mol. Biol. 2006, 13:392-399.
104. Yu Q., et al. Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat. Struct. Mol. Biol. 2004, 11:435-442.
105. Holtz C.M., et al. APOBEC3G cytosine deamination hotspots are defined by both sequence context and single-stranded DNA secondary structure. Nucleic Acids Res. 2013, 41:6139-6148.
106. Haché G., et al. The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain. J. Biol. Chem. 2005, 280:10920-10924.
107. Fang X., et al. Genome-wide adaptive complexes to underground stresses in blind mole rats Spalax. Nat. Commun. 2014, 5:3966.
108. Smith Z.D., Meissner A. DNA methylation: roles in mammalian development. Nat. Rev. Genet. 2013, 14:204-220.
109. Howell C.Y., et al. Genomic imprinting disrupted by a maternal effect mutation in the Dnmt1 gene. Cell 2001, 104:829-838.
110. Bhutani N., et al. Reprogramming towards pluripotency requires AID-dependent DNA demethylation. Nature 2010, 463:1042-1047.
111. Fritz E.L., Papavasiliou F.N. Cytidine deaminases: AIDing DNA demethylation?. Genes Dev. 2010, 24:2107-2114.
112. Franchini D-M., Petersen-Mahrt S.K. AID and APOBEC deaminases: balancing DNA damage in epigenetics and immunity. Epigenomics 2014, 6:427-443.
113. Hajkova P., et al. Genome-wide reprogramming in the mouse germ line entails the base excision repair pathway. Science 2010, 329:78-82.
114. Cortellino S., et al. Thymine DNA glycosylase is essential for active DNA demethylation by linked deamination-base excision repair. Cell 2011, 146:67-79.
115. Sabag O., et al. Establishment of methylation patterns in ES cells. Nat. Struct. Mol. Biol. 2014, 21:110-112.
116. Nabel C.S., et al. AID/APOBEC deaminases disfavor modified cytosines implicated in DNA demethylation. Nat. Chem. Biol. 2012, 8:751-758.
117. Rangam G., et al. AID enzymatic activity is inversely proportional to the size of cytosine C5 orbital cloud. PLoS ONE 2012, 7:e43279.
118. Abdouni H., et al. Zebrafish AID is capable of deaminating methylated deoxycytidines. Nucleic Acids Res. 2013, 41:5457-5468.
119. Suspène R., et al. Efficient 3eamination of 5-methylcytidine and 5-substituted cytidine residues in dna by human APOBEC3A cytidine deaminase. PLoS ONE 2013, 8:e63461.
120. Land A.M., et al. Endogenous APOBEC3A DNA cytosine deaminase is cytoplasmic and nongenotoxic. J. Biol. Chem. 2013, 288:17253-17260.
121. Carpenter M.A., et al. Methylcytosine and normal cytosine deamination by the foreign DNA restriction enzyme APOBEC3A. J. Biol. Chem. 2012, 287:34801-34808.
122. Santos F., et al. Active demethylation in mouse zygotes involves cytosine deamination and base excision repair. Epigenetics Chromatin 2013, 6:39.
123. Teperek-Tkacz M., et al. Epigenetic reprogramming: is deamination key to active DNA demethylation?. Reproduction 2011, 142:621-632.
124. Muñoz D.P., et al. Activation-induced cytidine deaminase (AID) is necessary for the epithelial-mesenchymal transition in mammary epithelial cells. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:E2977-E2986.
125. Sandoval J., Esteller M. Cancer epigenomics: beyond genomics. Curr. Opin. Genet. Dev. 2012, 22. 50-45.
126. Nik-Zainal S., et al. Mutational processes molding the genomes of 21 breast cancers. Cell 2012, 149:979-993.
127. Burns M.B., et al. APOBEC3B is an enzymatic source of mutation in breast cancer. Nature 2013, 494:366-370.
128. Burns M.B., et al. Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat. Genet. 2013, 45:977-983.
129. Roberts S.A., et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat. Genet. 2013, 45:970-976.
130. Taylor B.J., et al. DNA deaminases induce break-associated mutation showers with implication of APOBEC3B and 3A in breast cancer kataegis. Elife 2013, 2:e00534.
131. Nik-Zainal S., et al. Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer. Nat. Genet. 2014, 46:487-491.
132. Chan K., et al. An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers. Nat. Genet. 2015, 47:1067-1072.
133. Sieuwerts A.M., et al. Elevated APOBEC3B correlates with poor outcomes for estrogen-receptor-positive breast cancers. Horm. Cancer 2014, 5:405-413.
134. Nowarski R., Kotler M. APOBEC3 cytidine deaminases in double-strand DNA break repair and cancer promotion. Cancer Res. 2013, 73:3494-3498.
135. Caval V., et al. A prevalent cancer susceptibility APOBEC3A hybrid allele bearing APOBEC3B 3'UTR enhances chromosomal DNA damage. Nat. Commun. 2014, 5:5129.
136. Duggal N.K., Emerman M. Evolutionary conflicts between viruses and restriction factors shape immunity. Nat. Rev. Immunol. 2012, 12:687-695.
137. Duggal N.K., et al. The breadth of antiviral activity of Apobec3DE in chimpanzees has been driven by positive selection. J. Virol. 2011, 85:11361-11371.
138. Mulder L.C.F., et al. Cytidine deamination induced HIV-1 drug resistance. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:5501-5506.
139. Armitage A.E., et al. APOBEC3G-induced hypermutation of human immunodeficiency virus type-1 is typically a discrete 'all or nothing' phenomenon. PLoS Genet. 2012, 8:e1002550.
140. Feng Y., et al. Suppression of APOBEC3-mediated restriction of HIV-1 by Vif. Front. Microbiol. 2014, 5:450.
141. Richardson S.R., et al. APOBEC3A deaminates transiently exposed single-strand DNA during LINE-1 retrotransposition. Elife 2014, 3:e02008.
142. Zaranek A.W., et al. A survey of genomic traces reveals a common sequencing error, RNA editing, and DNA editing. PLoS Genet. 2010, 6:e1000954.
143. Ebrahimi D., et al. APOBEC3 has not left an evolutionary footprint on the HIV-1 genome. J. Virol. 2011, 85:9139-9146.
144. Knisbacher B.A., Levanon E.Y. DNA editing of LTR retrotransposons reveals the impact of APOBECs on vertebrate genomes. Mol. Biol. Evol. 2015, Published online November 4, 2015. 10.1093/molbev/msv239.